Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEP-Ru
- Development stage
- Unknown
- Lead developer
- Beijing Friendship Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**DEP-Ru** is an investigational salvage co-administration regimen for refractory or relapsed hemophagocytic lymphohistiocytosis. It combines oral ruxolitinib, a Janus kinase 1 and Janus kinase 2 inhibitor that suppresses cytokine-driven hyperinflammation, with liposomal doxorubicin, etoposide, and methylprednisolone. The chemotherapy and corticosteroid components provide cytotoxic, immunosuppressive, and anti-inflammatory activity. The regimen was developed clinically by Beijing Friendship Hospital and evaluated in the multicentre single-arm phase 2 study NCT03533790.
- Other names
- DEP-Ru regimenDEP-ruxolitinib regimenRu-DEP regimenruxolitinib + liposomal doxorubicin + etoposide + methylprednisolone
02
Targets
JAK2 (Janus kinase 2)TOP2A (DNA topoisomerase II)JAK1 (Janus kinase 1)GR (Glucocorticoid receptor)DNA
Beyond the preview
Go deeper on DEP-Ru.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEP-Ru.